CART-PSMA-TGFβRDN for Metastatic Castration-resistant Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Metastatic Castration-resistant Prostate CancerCART-PSMA-TGFβRDN - Biological
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer treatment that uses genetically modified T cells to attack prostate cancer cells. The goal is to see if the treatment is safe and works well against the cancer.

Eligible Conditions
  • Metastatic Castration-resistant Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
RBX7455
1
Benzyl Peroxide
1
Ketone ester + echocardiogram + PET FDG scanning visit.

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: Up to 15 years

Up to 15 years
Peripheral expansion and persistence of CART-PSMA-TGFβRDN
Up to 2 years
Cohort Expansion: Safety of CART-PSMA-TGFβRDN
Dose Escalation: Dose Identification of CART-PSMA-TGFβRDN
Feasibility of CART-PSMA-TGFβRDN
Preliminary efficacy of CART-PSMA-TGFβRDN as assessed by biochemical Objective Response Rate (ORR)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
RBX7455
1
Benzyl Peroxide
2
Ketone ester + echocardiogram + PET FDG scanning visit.

Trial Design

1 Treatment Group

Dose Escalation
1 of 1

Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: CART-PSMA-TGFβRDN · No Placebo Group · Phase 1

Dose EscalationExperimental Group · 4 Interventions: CART-PSMA-TGFβRDN, Cyclophosphamide, Fludarabine, Anakinra · Intervention Types: Biological, Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
FDA approved
Fludarabine
FDA approved
Anakinra
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 15 years

Who is running the clinical trial?

Tmunity TherapeuticsLead Sponsor
6 Previous Clinical Trials
304 Total Patients Enrolled
1 Trials studying Metastatic Castration-resistant Prostate Cancer
114 Patients Enrolled for Metastatic Castration-resistant Prostate Cancer

Eligibility Criteria

Age 18+ · Male Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The individual has confirmed prostate cancer and has metastatic castrate resistant prostate cancer, with levels of testosterone below 50 ng/mL.
The Prostate Working Group 3 has developed a set of criteria for diagnosing prostate cancer
The person has an estimated glomerular filtration rate of ≥ 60 mL/min, as estimated by the Modification of Diet in Renal Disease criteria.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be ≤ 2.5x the upper limit of normal (ULN) if the patient has hepatic metastases
The patient's serum total bilirubin level should be less than 1.5 mg/dL, except if the patient has known Gilbert's Syndrome, in which case the serum bilirubin level should be less than 3 mg/dL.
The absolute neutrophil count must be at least 1000/μL.
You have a hemoglobin level of at least 8 g/dL.
You have received at least two prior lines of systemic therapy for prostate cancer, including at least one second generation and/or CYP17α inhibitor and/or AR inhibitor.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top